BioTissue Cryopreserved Amniotic Membranes Featured in SECO 2026 Research on Complex Corneal Disease

MIAMI, February 23, 2026—New clinical findings presented at this week’s Southern Council of Optometrists (SECO) meeting in Atlanta highlight positive outcomes with cryopreserved amniotic membrane (CAM) in the management of complex ocular surface disease, including neurotrophic keratitis (NK) and recurrent corneal erosion (RCE). 

Two scientific posters outline treatment approaches and outcomes in patients with persistent corneal surface disease where conventional therapies provided insufficient relief. The case reports focus on epithelial recovery, symptom reduction, and visual acuity following cryopreserved amniotic membrane placement. 

In Successful Management of Recurrent Corneal Erosion with Cryopreserved Amniotic Membrane in a Post-LASIK Patient with Occupational Exacerbation, Seema Nanda, OD, reports outcomes in a 27-year-old post-LASIK patient with recurrent corneal erosion and persistent tearing, photophobia, blurred vision, and redness affecting daily work activities. Initial management with lubrication, bandage contact lens, and topical medications provided limited relief, resulting in 8 RCE episodes over 5 months. Treatment with cryopreserved amniotic membrane (BioTissue® Prokera® Slim) was associated with significant reduction in corneal staining and symptoms, improvement in visual acuity, and return to regular work function. Patient experienced recurrence of symptoms 19 months later, which was managed with another placement of CAM and resulted in complete resolution of corneal staining and symptoms for an additional 18 months. 

The second poster, Treatment of Stage 1 NK Secondary to Acoustic Neuroma Removal with Cryopreserved Amniotic Membrane, by Katherine Rachon, OD, describes a 77-year-old patient with stage 1 NK and reduced corneal sensitivity following removal of an acoustic neuroma of the right vestibular nerve, removal of neoplasm of the right eyelid, and prior cataract surgery. The patient presented with persistent superficial punctate keratitis and blurry vision despite topical therapy. Cryopreserved amniotic membrane (BioTissue CAM360 AmnioGraft®) was placed for 72 hours with eyelid closure support. Follow-up examination showed improvement from 3+ to trace superficial punctate keratitis (SPK), consistent with improved corneal epithelial integrity. 

“These case reports reflect a broader shift toward regenerative therapies in ocular surface care, particularly for patients with persistent epithelial disease that does not fully respond to conventional approaches,” said Ted Davis, President and CEO of BioTissue. “Over the past several years, we have seen growing adoption of cryopreserved amniotic membrane among eye care professionals as they look for therapies that better support healing of the ocular surface and in turn, improve quality of life for their patients.”  

Posters will be presented and displayed in the SECO exhibit hall. Dr. Nanda’s poster will be available during session #2 on Friday from 12 p.m. to 2 p.m., while Dr. Rachon’s poster will be featured during session #4 on Saturday from 9:45 a.m. to 11:45 a.m. For more information, visit https://attendseco.com/poster-sessions/. 

# # #

About BioTissue Holdings, Inc. 

BioTissue® is an emerging biotechnology company and leader in harnessing the unique properties of human birth tissue to facilitate regenerative healing, specializing in acute and chronic ocular surface conditions. BioTissue’s portfolio of cryopreserved amniotic membrane products are processed using its proprietary CryoTek® cryopreservation technology, designed to retain the tissue’s structural and functional integrity. The company continues to break new ground with Investigational New Drug (IND) applications as the company pursues Biologic License Applications (BLAs) for products to treat patients’ unmet clinical needs. BioTissue is committed to empowering healthcare professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since its inception, clinicians have performed over 1.2 million human procedures with its products and published over 440 peer-reviewed publications supporting BioTissue’s platform technology. Learn more at www.biotissue.com/.  

Media Contact 

Wendy Boyce 

McDougall Communications for BioTissue 

[email protected] or (585) 752-5805